Your Health, We Care
Release date: 2024-11-29 14:22:16 Recommended: 156
This product is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed during or after platinum-containing chemotherapy and carry epidermal growth factor receptor (EGFR) exon 20 insertion mutations. This product has been conditionally approved for marketing based on surrogate endpoints (objective response rate and duration of response in a single-arm clinical trial). Long-term clinical endpoint data have not yet been obtained and further confirmation is pending after marketing.
Vometinib is a drug used to treat non-small cell lung cancer (NSCLC) with EGFR mutations, but some patients may develop resistance. When vometinib becomes resistant, Exkivity can be considered. Exkivity, as a new type of EGFR-TKI drug, belongs to the same class of drugs as vometinib. It can block the activity of EGFR, thereby inhibiting the growth and spread of tumor cells. In clinical trials, Exkivity has shown good efficacy for NSCLC patients with EGFR mutations, especially for those who have received other EGFR-TKI drugs.
However, it should be noted that everyone's condition and physical condition are different, so the individual situation of the patient needs to be considered comprehensively when choosing a drug. Before using Exkivity, it is recommended that patients consult a professional doctor, who will develop the best treatment plan based on the patient's condition, drug resistance, and drug indications and contraindications.
Exkivity has shown outstanding advantages in many clinical trials. First, the remission time is long-lasting. The objective response rate (ORR) assessed by the independent review committee (IRC) was 28%, the ORR assessed by the investigator (INV) was 35%, and the median duration of remission (DoR) was as long as 15.8 months. Second, the survival time is prolonged. Exkivity improves the survival benefit of patients who have been treated with platinum, with a median progression-free survival (PFS) of 7.3 months and a median overall survival (OS) of 20.2 months. Finally, it has good safety. Exkivity is taken orally once a day, and its adverse reaction spectrum is consistent with common EGFR TKIs, with the most common being diarrhea, rash, paronychia, etc. Most adverse events are safe and controllable.
In addition, in the treatment of patients with EGFR ex20ins mutation non-small cell lung cancer who have received platinum chemotherapy and have disease progression, the disease control rate (DCR) of Exkivity is as high as 78%, and 84% of patients achieve tumor shrinkage. The results released in May 2022 showed that after more than a year of follow-up, the 1-year survival rate of patients treated with Exkivity reached 70%.
These clinical trial results fully demonstrate the significant efficacy and good safety of Exkivity in the treatment of lung cancer, bringing new hope to patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
The recommended dose of Exkivity is 160 mg, taken orally once a day until disease progression or unacceptable toxicity occurs.
As a lung cancer treatment drug, Exkivity has excellent efficacy, but it may also cause some side effects. Among them, gastrointestinal adverse reactions are more common, including nausea, vomiting, diarrhea, etc. According to statistics, about a certain proportion of patients will experience these symptoms during the use of Exkivity. Skin reactions are also one of the possible side effects, and patients may experience discomfort such as rash, itching, dryness, and peeling. In addition, some patients may experience abnormal liver function, manifested as increased liver enzyme levels. Diarrhea is also one of the common side effects of Exkivity, which may cause inconvenience to patients' lives. At the same time, respiratory tract infection is also one of the potential side effects during Exkivity treatment. Patients should pay close attention to respiratory symptoms, such as coughing and shortness of breath.
For gastrointestinal adverse reactions, doctors usually recommend that patients make appropriate dietary and lifestyle adjustments before and after taking the medicine. For example, eat in divided portions, avoid spicy or greasy foods, choose light and easily digestible foods, and drink plenty of water to alleviate these symptoms. If nausea and vomiting are more severe, the doctor may provide some medications to help control them.
For skin reactions, patients are advised to wash their skin regularly with a mild cleanser and avoid using irritating cosmetics. For some mild symptoms such as rashes and itching, they generally resolve on their own within a few weeks. But for severe symptoms, the doctor may recommend some topical medications to relieve them.
When using Exkivity, regular blood tests are crucial to monitor the patient's liver function in a timely manner. If abnormal liver function is found, the doctor may adjust the drug dose or suspend treatment to prevent further damage.
For diarrhea, it is crucial to maintain adequate water intake to prevent dehydration. The doctor may advise the patient to avoid foods that may aggravate diarrhea, such as spicy and greasy foods. If diarrhea does not improve or additional signs or symptoms are reported, standard medical practice interventions should be performed and electrolytes should be monitored. If severe diarrhea occurs, interrupt this product treatment and reduce subsequent doses.
For respiratory infections, patients should pay close attention to respiratory symptoms such as cough, shortness of breath, etc. It is crucial to seek medical attention promptly when feeling signs of respiratory infection in order to receive appropriate treatment.
